Myelofibrosis: biology and treatment options (Q36922494)

17 August 2017

1 reference

title

Myelofibrosis: biology and treatment options (English)

1 reference

17 August 2017

1 reference

Francisco Cervantes

1

1 reference

17 August 2017

publication date

1 October 2007

1 reference

European journal of haematology. Supplementum

17 August 2017

published in

1 reference

17 August 2017

issue

68

1 reference

17 August 2017

page(s)

13-17

1 reference

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Advances in the therapy of chronic idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.2007.00937.X

10.1111/J.1600-0609.2007.00937.X

21 January 2018

Identifiers

DOI

0 references

1 reference